While spring breakers and beachgoers sunbathe below, the Destin resident is shrouded head to toe in compression gear. Below his white and black-striped sun cap and Oakley sunglasses, the 34-year-old ...

PHILADELPHIA—It has been a big year for Halozyme Therapeutics, and 2019’s not over yet. The biotech inked its ninth licensing deal for its drug delivery platform with its first biotech partner, saw ...

Forbes contributors publish independent expert analyses and insights. We provide aggregated data on dividend stocks. Sep 17, 2014, 10:37am EDT Sep 17, 2014, 10:37am EDT This article is more than 10 ...

Helen Torley, President and CEO of Halozyme Therapeutics, INC. (NASDAQ:HALO), sold 10,000 shares of common stock on April 6, 2026, according to a Form 4 filing with the Securities and Exchange ...

In a merger between two subcutaneous drug delivery companies, Halozyme Therapeutics is paying $750 million in cash to acquire Elektrofi. Aside from the $750 million upfront payment, the deal also ...

Monday - Friday, 6:00 - 7:00 PM ET Shares of Halozyme Therapeutics soared more than 17 percent on Thursday after the company reported very strong phase 2 results for its pancreatic cancer drug.

Helen Torley, the President and CEO of Halozyme Therapeutics NASDAQ:HALO, sold a total of 60,500 shares of common stock between November 10 and November 12, 2025. The sales, executed under a ...